Vaccinia Virus Complement Control Protein Diminishes Formation of Atherosclerotic Lesions: Complement Is Centrally Involved in Atherosclerotic Disease

• Published in: Annals of the New York Academy of Sciences 2005-11, Vol.1056 (1), p.1-15
• Main Authors: THORBJORNSDOTTIR, PERLA, KOLKA, RAGNHILDUR, GUNNARSSON, EGGERT, BAMBIR, SLAVKO H., THORGEIRSSON, GUÐMUNDUR, KOTWAL, GIRISH J., ARASON, GUÐMUNDUR J.
• Format: Article
• Language: English
• Subjects: Animals; atherosclerosis; Atherosclerosis - pathology; Atherosclerosis - prevention & control; C57BL/6; complement; Complement Activation; Complement System Proteins - physiology; Dietary Fats; Disease Models, Animal; Female; inflammation; Mice; Mice, Inbred C57BL; mouse model; Myocardium - pathology; Vaccinia virus; Vaccinia virus - physiology; vaccinia virus complement control protein; Viral Proteins - pharmacokinetics; Viral Proteins - pharmacology; Viral Proteins - therapeutic use
• ISSN: 0077-8923; 1749-6632
• DOI: 10.1196/annals.1352.001

Complement is known to be activated in atherosclerotic lesions, but the importance of this event in disease pathology is a matter of debate. Studies of rabbits fed a high‐fat diet have indicated complement activation as a rate‐limiting step, whereas results from genetically modified mouse strains (ApoE−/− or LDLR−/−) have failed to support this finding. To resolve whether this reflects differences between species or between genetically driven and diet‐induced disease, we studied the effect of a complement inhibitor, vaccinia virus complement control protein (VCP), on C57BL/6 mice, the background strain of ApoE−/− and LDLR−/− mice. Atherosclerosis was induced by a high‐fat diet, and VCP (20 mg/kg) was injected once per week after the eighth week. Fatty streak development was monitored at 15 weeks by microscopic examination of oil red‐O‐stained sections from the root of the aorta. VCP injections led to significant (50%) reduction of lesion size (P= 0.004). Lesions were marked by gradual accumulation of lipids and macrophages but did not develop beyond the fatty streak stage. VCP activity disappeared from serum in 4 days, and the possibility therefore exists that a higher level of protection may be achieved by more frequent injections. We conclude that the development of fatty streaks in diet‐induced atherosclerotic disease can be significantly retarded by prophylactic treatment with a complement inhibitor. These results support previous findings from complement‐deficient rabbits and suggest that the pathogenesis of atherosclerosis in diet‐induced disease differs from that induced by major defects in lipid metabolism.